DDInter825 DDInter535
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255647,L44612]
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glimepiride {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Diazoxide
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorothiazide
Chlorothiazide {u} (Compound) binds {v} (Gene) CA1
CA1 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) interacts with {v} (Gene) ABCC8
ABCC8 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glimepiride {u} (Compound) binds {v} (Gene) ABCC8
ABCC8 {u} (Gene) interacts with {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Diazoxide
Glimepiride {u} (Compound) causes {v} (Side Effect) Anorexia
Anorexia {u} (Side Effect) is caused by {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroflumethiazide
Hydroflumethiazide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Diazoxide
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is associated with {v} (Disease) hypertension
hypertension {u} (Disease) is palliated by {v} (Compound) Diazoxide
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) regulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Diazoxide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Glimepiride (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Diazoxide (Compound)
Glimepiride (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Diazoxide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) binds CA1 (Gene) and CA1 (Gene) is bound by Diazoxide (Compound)
Glimepiride (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) interacts with ABCC8 (Gene) and ABCC8 (Gene) is bound by Diazoxide (Compound)
Glimepiride (Compound) binds ABCC8 (Gene) and ABCC8 (Gene) interacts with KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Diazoxide (Compound)
Glimepiride (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Diazoxide (Compound)
Glimepiride (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is associated with hypertension (Disease) and hypertension (Disease) is palliated by Diazoxide (Compound)
Glimepiride (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) regulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Diazoxide (Compound)